Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
|ClinicalTrials.gov Identifier: NCT00094484|
Recruitment Status : Completed
First Posted : October 20, 2004
Last Update Posted : May 8, 2013
|Condition or disease||Intervention/treatment||Phase|
|Kidney Disease Chronic Kidney Disease||Drug: Cinacalcet HCl||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||400 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis|
|Study Start Date :||October 2004|
- Proportion of subjects with a mean reduction of greater than or equal to 30% in iPTH at 32 weeks
- Changes in iPTH at 32 weeks.
- Safety and tolerability of cinacalcet at 32 weeks.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00094484